Presynaptic Control of Serotonin on Striatal Dopamine Function

Overview

Journal Psychopharmacology (Berl)

Specialty Pharmacology

Date 2010 Oct 19

PMID 20953589

Citations 38

Authors

Sylvia Navailles

Philippe De Deurwaerdere

Affiliations

Soon will be listed here.

Abstract

Rationale: The influences of the serotonergic system on dopamine (DA) neuron activity have received considerable attention during the last three decades due to the real opportunity to improve disorders related to central DA neuron dysfunctions such as Parkinson's disease, schizophrenia, or drug abuse with serotonergic drugs. Numerous biochemical and behavioral data indicate that serotonin (5-HT) affects dopaminergic terminal function in the striatum.

Objective: The authors propose a thorough examination of data showing controversial effects induced by striatal 5-HT on dopaminergic activity.

Results: Inhibitory and excitatory effects of exogenous 5-HT have been reported on DA release and synthesis, involving various striatal 5-HT receptors. 5-HT also promotes an efflux of DA through reversal of the direction of DA transport. By analogy with the mechanism of action described for amphetamine, the consequences of 5-HT entering DA terminals might explain both the excitatory and inhibitory effects of 5-HT on presynaptic DA terminal activity, but the physiological relevance of this mechanism is far from clear. The recent data suggest that the endogenous 5-HT system affects striatal DA release in a state-dependent manner associated with the conditional involvement of various 5-HT receptors such as 5-HT(2A), 5-HT(2C), 5-HT(3), and 5-HT(4) receptors.

Conclusion: Methodological and pharmacological issues have prevented a comprehensive overview of the influence of 5-HT on striatal DA activity. The distribution of striatal 5-HT receptors and their restricted influence on DA neuron activity suggest that the endogenous 5-HT system exerts multiple and subtle influences on DA-mediated behaviors.

Citing Articles

Impact of Serotonergic 5HT and 5HT Receptor Activation on the Respiratory Response to Hypercapnia in a Rat Model of Parkinson's Disease.

Andrzejewski K, Orlowska M, Zaremba M, Joniec-Maciejak I, Kaczynska K Int J Mol Sci. 2024; 25(8).

PMID: 38673988 PMC: 11050428. DOI: 10.3390/ijms25084403.

Parkinsonian phenotypes induced by Synphilin-1 expression are differentially contributed by serotonergic and dopaminergic circuits and suppressed by nicotine treatment.

Carvajal-Oliveros A, Dominguez-Baleon C, Sanchez-Diaz I, Zambrano-Tipan D, Hernandez-Vargas R, Campusano J PLoS One. 2023; 18(3):e0282348.

PMID: 36857384 PMC: 9977059. DOI: 10.1371/journal.pone.0282348.

Depression-Associated Gene-Deficiency Induces Alterations in the Monoaminergic Neurotransmission Enhancing Time-Dependent Sensitization to Amphetamine in Male Mice.

Kaare M, Jayaram M, Jagomae T, Singh K, Kilk K, Mikheim K Brain Sci. 2022; 12(12).

PMID: 36552158 PMC: 9776224. DOI: 10.3390/brainsci12121696.

An Early Disturbance in Serotonergic Neurotransmission Contributes to the Onset of Parkinsonian Phenotypes in .

Zarate R, Hidalgo S, Navarro N, Molina-Mateo D, Arancibia D, Rojo-Cortes F Cells. 2022; 11(9).

PMID: 35563850 PMC: 9105628. DOI: 10.3390/cells11091544.

Perspective: Gestational Tryptophan Fluctuation Altering Neuroembryogenesis and Psychosocial Development.

Huang X, Feng Z, Cheng H Cells. 2022; 11(8).

PMID: 35455949 PMC: 9032700. DOI: 10.3390/cells11081270.

References

Descarries L, Mechawar N . Ultrastructural evidence for diffuse transmission by monoamine and acetylcholine neurons of the central nervous system. Prog Brain Res. 2000; 125:27-47. DOI: 10.1016/S0079-6123(00)25005-X. View

Ng N, Lee H, Wong P . Regulation of striatal dopamine release through 5-HT1 and 5-HT2 receptors. J Neurosci Res. 1999; 55(5):600-7. DOI: 10.1002/(SICI)1097-4547(19990301)55:5<600::AID-JNR7>3.0.CO;2-#. View

Jacocks 3rd H, Cox B . Serotonin-stimulated release of [3H]dopamine via reversal of the dopamine transporter in rat striatum and nucleus accumbens: a comparison with release elicited by potassium, N-methyl-D-aspartic acid, glutamic acid and D-amphetamine. J Pharmacol Exp Ther. 1992; 262(1):356-64. View

Yamamoto B, Nash J, Gudelsky G . Modulation of methylenedioxymethamphetamine-induced striatal dopamine release by the interaction between serotonin and gamma-aminobutyric acid in the substantia nigra. J Pharmacol Exp Ther. 1995; 273(3):1063-70. View

De Deurwaerdere P, Stinus L, Spampinato U . Opposite change of in vivo dopamine release in the rat nucleus accumbens and striatum that follows electrical stimulation of dorsal raphe nucleus: role of 5-HT3 receptors. J Neurosci. 1998; 18(16):6528-38. PMC: 6793211. View

Bunin M, Wightman R . Quantitative evaluation of 5-hydroxytryptamine (serotonin) neuronal release and uptake: an investigation of extrasynaptic transmission. J Neurosci. 1998; 18(13):4854-60. PMC: 6792557. View

Loric S, Launay J, Colas J, Maroteaux L . New mouse 5-HT2-like receptor. Expression in brain, heart and intestine. FEBS Lett. 1992; 312(2-3):203-7. DOI: 10.1016/0014-5793(92)80936-b. View

Carboni E, Acquas E, Frau R, Di Chiara G . Differential inhibitory effects of a 5-HT3 antagonist on drug-induced stimulation of dopamine release. Eur J Pharmacol. 1989; 164(3):515-9. DOI: 10.1016/0014-2999(89)90259-8. View

Youdim M, Feldman S, Pappas G, Pollard H . Serotonin metabolism and the nature of monoamine oxidase in squid central nervous system. Brain Res. 1986; 381(2):300-4. DOI: 10.1016/0006-8993(86)90080-6. View

10.

Egerton A, Ahmad R, Hirani E, Grasby P . Modulation of striatal dopamine release by 5-HT2A and 5-HT2C receptor antagonists: [11C]raclopride PET studies in the rat. Psychopharmacology (Berl). 2008; 200(4):487-96. DOI: 10.1007/s00213-008-1226-4. View

11.

Kuhr W, Ewing A, Near J, Wightman R . Amphetamine attenuates the stimulated release of dopamine in vivo. J Pharmacol Exp Ther. 1985; 232(2):388-94. View

12.

Martin-Cora F, Pazos A . Autoradiographic distribution of 5-HT7 receptors in the human brain using [3H]mesulergine: comparison to other mammalian species. Br J Pharmacol. 2003; 141(1):92-104. PMC: 1574165. DOI: 10.1038/sj.bjp.0705576. View

13.

De Deurwaerdere P, Bonhomme N, Lucas G, Le Moal M, Spampinato U . Serotonin enhances striatal dopamine outflow in vivo through dopamine uptake sites. J Neurochem. 1996; 66(1):210-5. DOI: 10.1046/j.1471-4159.1996.66010210.x. View

14.

Porras G, Di Matteo V, Fracasso C, Lucas G, De Deurwaerdere P, Caccia S . 5-HT2A and 5-HT2C/2B receptor subtypes modulate dopamine release induced in vivo by amphetamine and morphine in both the rat nucleus accumbens and striatum. Neuropsychopharmacology. 2002; 26(3):311-24. DOI: 10.1016/S0893-133X(01)00333-5. View

15.

Deutch A, Moghaddam B, Innis R, Krystal J, Aghajanian G, Bunney B . Mechanisms of action of atypical antipsychotic drugs. Implications for novel therapeutic strategies for schizophrenia. Schizophr Res. 1991; 4(2):121-56. DOI: 10.1016/0920-9964(91)90030-u. View

16.

Waldmeier P . Serotonin--dopamine interactions in the nigrostriatal system. Eur J Pharmacol. 1979; 55(4):363-73. DOI: 10.1016/0014-2999(79)90110-9. View

17.

Willins D, Meltzer H . Serotonin 5-HT2C agonists selectively inhibit morphine-induced dopamine efflux in the nucleus accumbens. Brain Res. 1998; 781(1-2):291-9. DOI: 10.1016/s0006-8993(97)01267-5. View

18.

Benuck M, Reith M . Dopamine releasing effect of phenylbiguanide in rat striatal slices. Naunyn Schmiedebergs Arch Pharmacol. 1992; 345(6):666-72. DOI: 10.1007/BF00164581. View

19.

Westfall T, Tittermary V . Inhibition of the electrically induced release of [3H]dopamine by serotonin from superfused rat striatal slices. Neurosci Lett. 1982; 28(2):205-9. DOI: 10.1016/0304-3940(82)90153-7. View

20.

Varnas K, Thomas D, Tupala E, Tiihonen J, Hall H . Distribution of 5-HT7 receptors in the human brain: a preliminary autoradiographic study using [3H]SB-269970. Neurosci Lett. 2004; 367(3):313-6. DOI: 10.1016/j.neulet.2004.06.025. View